한글목차

시장 개요

세계 스타가르트병 치료제 시장은 2022년 1억 9,710만 달러, 2030년에는 13억 8,560만 달러에 달할 것으로 예상되며, 수익성 있는 성장이 예상됩니다. 세계 스타가르트병 치료제 시장은 예측 기간(2023-2030년) 동안 28.8%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

스타가르트병은 유전성 안질환입니다. 스타가르트병은 주로 어린 시절부터 청소년기에 발병하며, 시간이 지남에 따라 시력 저하가 진행됩니다. 현재 스타가르트병에 대한 치료법은 확립되어 있지 않지만, 병을 조절하고 발병을 막기 위한 치료 전략의 개발은 큰 진전을 보이고 있습니다.

시장 역학

치료법 발전이 예측 기간 동안 세계 스타가르트병 치료제 시장의 성장을 견인하고 있습니다.

치료법을 임상 연구로 발전시키고 이를 필요로 하는 환자에게 전달하기 위해 최근 옵시스 테라퓨틱스(Opsis Therapeutics)가 설립되었으며, 한 층은 시력을 가능하게 하는 광수용체의 전구체 역할을 합니다. 이 층의 줄기세포는 이식 후 광수용체로 성장합니다.

성숙한 망막색소상피(RPE) 세포는 광수용체에 음식을 공급하고 노폐물을 제거합니다. 패치 구조의 골격은 얇은 플라스틱 필름입니다. 세포는 차폐되고 층은 생분해 성 젤로 서로 연결됩니다.

줄기세포 치료, 세계 스타가르트병 치료제 시장에 성장 기회 제공

손상된 망막세포를 복구하기 위해 줄기세포를 활용하는 것도 개발 분야 중 하나입니다. 망막색소상피(RPE) 세포는 환자 자신의 세포로 만든 인공줄기세포(iPSC)로 개발하여 안구에 재이식할 수 있습니다. 동물실험에서 이 방법은 질병이나 손상된 세포를 대체하는 데 유망한 것으로 나타났으며, 현재 사람에 대한 안전성과 유효성을 확인하기 위한 임상시험이 진행 중입니다.

COVID-19의 영향 분석

코로나19의 대유행은 스타가르트병 치료제 시장에 큰 영향을 미치고 있습니다. 환자 모집의 제한, 의료 시설에 대한 접근성 제한, 코로나19에 대한 자원의 우선 순위 지정으로 인해 세계적으로 현재 진행 중인 임상시험이 중단됐습니다. 이러한 중단으로 인해 스타가르트병 치료제의 임상시험 개발이 지연되고, 규제 당국의 승인과 시장 진입에 필요한 시간이 늘어날 수 있습니다.

러시아-우크라이나 분쟁 분석

러시아-우크라이나 분쟁이 스타가르트병 치료제 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁의 직접적인 영향을 받은 지역에서는 병원, 진료소, 연구기관 등 의료시설이 파괴되거나 접근이 불가능할 수 있습니다. 스타가르트병 치료제 관련 의료 서비스 제공, 임상시험 수행 또는 연구 수행 능력은 이러한 혼란으로 인해 영향을 받을 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 조사 활동 활성화
  • 성장 억제요인
    • 전문가 부족
  • 기회
    • 치료 진보
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 미충족 요구
• 규제 분석

제6장 COVID-19 분석

제7장 러시아·우크라이나 전쟁 분석

제8장 인공지능(AI) 분석

제9장 약제 유형별

• LBS-008
• Emixustat

제10장 연령층별

• 소아
• 성인

제11장 유통 채널별

• 병원 약국
• 소매 약국
• 온라인 약국

제12장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제13장 경쟁 구도

• 경쟁 시나리오
• 제품 벤치마킹
• 기업 점유율 분석
• 주요 발전과 전략

제14장 기업 개요

• Kubota Pharmaceutical Holdings Co., Ltd.
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Stargazer Pharmaceuticals Inc
• Sanofi S.A.
• Alkeus Pharmaceuticals Inc
• Astellas Pharma Inc.
• CHABiotech CO., Ltd.
• ReVision Therapeutics, Inc.
• Lin BioScience, Inc.
• Biogen Inc.
• F. Hoffmann-La Roche AG

제15장 부록

영문목차

Market Overview

The Global Stargardt Disease Therapeutics Market reached US$ 197.1 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,385.6 million by 2030. The global Stargardt Disease Therapeutics market is expected to exhibit a CAGR of 28.8% during the forecast period (2023-2030).

The part of the retina that is responsible for clear, central vision, the macula, is harmed by Stargardt disease, an inherited eye condition. It often first appears throughout childhood or adolescence and over time may cause progressive visual loss. While there is now no treatment for Stargardt disease, there has been substantial advancement in the creation of therapeutic strategies to control the condition and maybe halt its development.

Market Dynamics

Advancement in Therapy Is Boosting The Global Stargardt Disease Therapeutics Market Growth During The Forecast Period.

To advance the therapy into and through a clinical study and out to the patients who need it, Opsis Therapeutics was recently founded, two layers make up the patch. One layer will act as a precursor for photoreceptors that enable vision. The stem cells in this layer will develop into photoreceptors after transplantation.

Mature retinal pigment epithelial (RPE) cells, which provide food and waste removal for photoreceptors, will make up the other layer. The backbone of the patch's structure will be a thin plastic film. The cells will be shielded and the layers will be held together by a biodegradable gel.

Stem Cell Therapy Provides The Global Stargardt Disease Therapeutics Market Growth Opportunities

Utilizing stem cells to repair damaged retinal cells is another area of development. Retinal pigment epithelium (RPE) cells can be developed from induced pluripotent stem cells (iPSCs) produced from a patient's own cells and re-implanted into the eye. In animal research, this method has shown promise for replacing sick or damaged cells, and clinical trials are now being conducted to determine its safety and effectiveness in people.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Stargardt disease therapeutics market. Due to limitations on patient recruitment, restricted access to healthcare facilities, and the prioritization of resources towards COVID-19, the pandemic has disrupted current clinical trials across the globe. This setback might have slowed down the development of clinical trials for treatments for Stargardt's illness, thereby increasing the amount of time needed for regulatory clearances and market entry.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the Stargardt disease therapeutics market is complex and multifaceted. Healthcare facilities, including as hospitals, clinics, and research institutes, may have been destroyed or made inaccessible in areas directly impacted by the conflict. The capacity to deliver healthcare, perform clinical trials, or conduct research on Stargardt Disease Therapeutics may be impacted by this disruption.

Segment Analysis

The global Stargardt disease therapeutics market is segmented based on drug type, age group, distribution channel, and region.

The LBS-008 Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The LBS-008 segment accounted for the highest market stake accounting for approximately 54.3% of the Stargardt disease therapeutics market in 2022. LBS-008, or Tinlarebant, If approved, would offer a cutting-edge therapy alternative where none now exists. To prevent the buildup of harmful vitamin A byproducts in ocular tissue, LBS-008 is an oral once-daily medication that can lower and sustain the distribution of vitamin A (retinol) to the eye.

The capacity of LBS-008 to decrease and maintain the level of serum retinol-binding protein 4, or RBP4, which transports retinol from the liver to the eye, results in this effect. LBS-008 has proven its target specificity and potency in clinical trials, and according to researchers, it may have clinical value for treating Stargardt (STGD1) patients.

Geographical Analysis

The Increasing Number Of Patients with Stargardt disease, and Advancement in Stargardt Disease Therapeutics Dominate The North American Region.

North America is expected to dominate the Stargardt disease therapeutics market, accounting for around 42.7% of this market. This disorder affects about 1 in 10,000 persons. In the United States, there are 30,000 to 200,000 persons who have Stargardt illness. With several academic institutions and research organizations actively pursuing improvements in the field of ophthalmology, North America is a hotspot for scientific research and development. These organizations work together with pharma companies and other stakeholders to provide cutting-edge treatments for Stargardt's illness.

Competitive Landscape

The major global players in the market include: Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG among others.

Why Purchase the Report?

• To visualize the global Stargardt disease therapeutics market segmentation based on the product, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Stargardt disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Stargardt disease therapeutics market report would provide approximately 61 tables, 55 figures, and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Age Group
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing research activities
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of professionals
  • 4.1.3. Opportunity
    • 4.1.3.1. Advancement in therapy
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Drug Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.1.2. Market Attractiveness Index, By Drug Type
• 9.2. LBS-008*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Emixustat

10. By Age Group

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 10.1.2. Market Attractiveness Index, By Age Group
• 10.2. Children*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Adult

11. By Distribution Channel

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
• 11.1.2. Market Attractiveness Index, By Distribution Channel
• 11.2. Hospital Pharmacies*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Retail Pharmacies
• 11.4. Online Pharmacies

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. The U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. The U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Kubota Pharmaceutical Holdings Co., Ltd.*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Stargazer Pharmaceuticals Inc
• 14.3. Sanofi S.A.
• 14.4. Alkeus Pharmaceuticals Inc
• 14.5. Astellas Pharma Inc.
• 14.6. CHABiotech CO., Ltd.
• 14.7. ReVision Therapeutics, Inc.
• 14.8. Lin BioScience, Inc.
• 14.9. Biogen Inc.
• 14.10. F. Hoffmann-La Roche AG

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us